• Join
  • Login
  • Contact

Search abstracts

Integrated modeling of the effect of RDEA3170 on serum uric acid and renal excretion rate of uric acid

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: LEANDER, Jacob (AstraZeneca, Quantitative Clinical Pharmacology, Mölndal, Sweden)
  • Co-author(s): Jacob Leander: Quantitative Clinical Pharmacology, AstraZeneca, Gothenburg, Sweden
    Sergey Aksenov: Quantitative Clinical Pharmacology, AstraZeneca, Waltham, United States
    Jesse Hall: Ardea Biosciences, San Diego, United States
    Ulf Eriksson: Quantitative Clinical Pharmacology, AstraZeneca, Gothenburg, Sweden
  • Abstract:


    RDEA3170 is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of gout and asymptomatic hyperuricemia. RDEA3170 inhibits the uric acid transporter URAT1, which is responsible for most reabsorption of urate from the renal tubular lumen, thereby increasing the excretion of uric acid and lowering


  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses